Company Overview and News

Yinson Q1 earnings above forecast as CIMB Research ups target price

Yinson Holdings Bhd’s FY1/18 core net profit of RM355m was 12% higher than CIMB Equities Research’s forecast.
Upvote Downvote

Yinson quarterly net profit up to RM57mil, declares special dividend

The improved results were driven by the chartering commencement of the floating production, storage and offloading (FPSO) vessel John Agyekum Kufuor (pic) in June 2017 and the stronger US dollar, the FPSO service provider said in a filing with Bursa Malaysia yesterday.
Upvote Downvote

Yinson boosts payout on higher net profit

KUALA LUMPUR: Yinson Holdings Bhd on Thursday said net profit increased 11.6% to RM57.1mil in the fourth quarter ended Jan 31 (FY18), as revenue surged 39% to RM257.4mil.
Upvote Downvote

Analysts still positive on Yinson

PETALING JAYA: Analysts remained positive of their outlook on Yinson Holdings Bhd despite a possible termination of its US$1bil charter contract for its floating production, storage and offloading (FPSO) facility in Vietnam.
Upvote Downvote

Yinson JV ordered to halt ops for Vietnam job

“Pending the resolution of this matter, and in compliance with the notice, PTSC Ca Rong Do will endeavour to take all reasonable action to mitigate the effects of the force majeure event,” Yinson said.
Upvote Downvote

Yinson unit buys up remaining stake in Anteros for RM36.75mil

In its statement to Bursa Malaysia, Yinson said its indirect wholly-owned subsidiary Yinson Heather Ltd (YHL) bought the stake in ARO from Four Vanguard Servicos E Navegacao LDA (FVSN) yesterday
Upvote Downvote

Yinson takes full control of Anteros Rainbow Offshore

PETALING JAYA: Yinson Holdings Bhd is buying out its minority partner in Anteros Rainbow Offshore Pte Ltd (ARO) - a  firm involved in leasing of floating, production, storage and offloading unit - for US$9mil (RM36.75mil).
Upvote Downvote

CIMB Research retains Add for Yinson

KUALA LUMPUR: CIMB Equities Research is retaining its Add for Yinson Holdings Bhd with a slightly lower target price of RM4.81 as it has deducted the perpetual securities from its sum-of-parts valuation as it had previously treated it as equity.   It said on Monday the oil and gas services provider delivered a 9MFY18 core net profit that made up 93% of its previous full-year forecast, due to lower-than-expected taxes.
Upvote Downvote

Yinson growth tops estimates in third quarter

KUALA LUMPUR: It’s not all gloom and doom in the oil and gas sector, with Yinson Holdings Bhd giving investors a rare treat of better than expected latest quarterly results.
Upvote Downvote

Few surprises expected from Yinson’s nine-month financial results

PETALING JAYA: Yinson Holdings Bhd ’s nine months results for the financial year ending Jan 31, 2018 (9M18) due this month is expected to yield minimal surprises, according to Maybank Investment Bank Research.
Upvote Downvote

Yinson Energy files affidavit

The said contract is between JX Nippon Oil & Gas Exploration (Malaysia) Ltd and THHE to Yinson Energy.
Upvote Downvote

Trading ideas: Serba Dinamik, Yinson, Gas Malaysia, Titijaya Land

KUALA LUMPUR: Serba Dinamik Holdings Bhd, Yinson Holdings Bhd , Gas Malaysia, Titijaya Land are among the stocks to watch on Thursday, according to JF Apex Research.
Upvote Downvote

Yinson sells stake in unit for RM489mil

In a Bursa Malaysia filing, Yinson said that upon the completion of the proposed disposal of 53.74 million shares in YPWAPL, the company would cease to be a wholly owned subsidiary of the group and would instead be an indirect 74%-owned subsidiary
Upvote Downvote

Yinson moves closer to RM484mil sale of stake in FPSO unit

Tags / Keywords: Corporate News , Oil & Gas , Yinson Holdings Bhd , Sumitomo Corp
Upvote Downvote

Mokhzani no longer Sapura Energy substantial shareholder

He would have netted RM578mil in proceeds from the share sale based on the stock’s closing price of RM1.50 on that day.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...